Morgan Stanley Erytech Pharma S.A. Transaction History

Morgan Stanley

  • $1.35 Trillion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022
SELL
$2.15 - $6.21 $636 - $1,838
-296 Closed
0 $0
Q3 2021

Nov 15, 2021
BUY
$4.11 - $6.47 $1,216 - $1,915
296 New
296 $2,000

About Erytech Pharma S.A.

ERYP Quotes by TradingView
  • Ticker ERYP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,018,600
  • Market Cap $16.8M
  • Description
  • ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of...
More about ERYP
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email